2018 Annual Meeting | C57 - Developing the Treatments of Tomorrow II: Clinical Trials in Neurology

Date Sunday 04/22/18

Time 03:30 PM - 05:30 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Jeffrey M. Gelfand, MD, MAS, FAAN

Topic(s)

Learning Objectives Participants should be able to understand differences between early- and late-stage clinical trials and their role in the drug development pipeline, assess the strengths and weaknesses of various clinical trial designs, apply appropriate statistical approaches, and understand regulatory issues.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Professionalism, Medical Knowledge, Systems-based Practice

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist

Teaching Styles Didactic, Interactive

Event Timeline
03:30 PM - 03:40 PM	Luncheon	Introduction: Clinical Trials in the Drug Development Pipeline Jeffrey M. Gelfand, MD, MAS, FAAN
03:40 PM - 04:05 PM	Speaker	Early and Late Stage Clinical Trials in Neurology Gilmore N. O'Neill, MD, MB, MRCPI
04:05 PM - 04:25 PM	Speaker	Statistical Considerations for Clinical Trials in Neurology Christopher Coffey, PhD, FAAN
04:25 PM - 04:45 PM	Speaker	Regulatory Considerations for Clinical Trials in Neurology Lei Xu, MD
04:45 PM - 05:05 PM	Speaker	Innovations in Clinical Trial Design and Implementation Jeffrey M. Gelfand, MD, MAS, FAAN
05:05 PM - 05:30 PM	Q&A	Faculty Panel / Discussion / Questions and Answers

Faculty Disclosures
Jeffrey M. Gelfand, MD, MAS, FAAN	Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant and Expert, Vaccine Injury Compensation Program with United States Health and Human Services and Department of Justice. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.
Gilmore N. O'Neill, MD, MB, MRCPI	No disclosure on file
Lei Xu, MD	No disclosure on file
Christopher Coffey, PhD, FAAN	Dr. Coffey has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Coffey has received research support from NIH. The institution of Dr. Coffey has received research support from Michael J Fox Foundation.